吴婷，教授，博士生导师，国家传染病诊断试剂与疫苗工程技术研究中心“临床试验与流行病学研究”组组长。主要研究方向为疫苗临床试验和传染病的流行病学研究。 教育背景 1990-1994 上海医科大学 药物化学专业 本科 1994-1997 上海医科大学 生物合成药物化学专业 硕士 1997-2000 复旦大学 生物合成药物化学专业 博士 工作经历 2000-2002 养生堂有限公司 工程师 2003-2009 厦门大学生命科学学院 讲师 2009-2011 厦门大学生命科学学院 副教授 2011-2015 厦门大学公共卫生学院副教授 2015-至今 厦门大学公共卫生学院 教授、博士生导师

主要研究方向为疫苗临床试验和传染病的流行病学研究，包括人乳头瘤病毒（HPV）系列疫苗的临床研究及相关流行病学研究、新型冠状病毒疫苗系列临床研究、戊型肝炎病毒相关流行病学研究、水痘带状疱疹病毒疫苗临床研究等。作为项目负责人之一完成HPV 16/18型双价疫苗的临床研究，该疫苗于2019年12月正式获批，成为首个上市的国产宫颈癌疫苗，2021年10月通过世界卫生组织预认证（PQ）。曾作为主要研究人员之一完成国家一类新药重组戊型肝炎病毒疫苗III期临床试验，该疫苗现已获得新药证书和生产文号，成为世界上第一个成功上市的戊肝疫苗。作为临床研究负责人主持我国新冠疫苗5条主要技术路线当中鼻喷流感病毒载体新冠肺炎疫苗的全球多中心III期临床试验，该疫苗于2022年12月被纳入我国紧急使用。作为主要研究人员主持或参与多项国家传染病重大科技专项、国家自然科学基金项目、福建省科技重大专项等多个项目。

[1] Huang SJ#, Zhang XF#, Su YY#, Zhuang CL#, Tang ZM#, Huang XC, Chen Q, Zhu KX, Hu XW, Ying D, Liu XH, Jiang HM, Zang X, Wang ZZ, Yang CL, Liu DL, Wang YJ, Tang Q, Shen WT, Cao HH, Pan HR, Ge SX, Huang Y, Wu T*, Zheng ZZ*, Zhu FC*, Zhang J*, Xia NS*. Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024 Mar 2;403(10429):813-823. (共通讯作者) [2] ] Pan HX#, Qiu LX#, Liang Qi#, Chen Z#, Zhang ML, Liu S, Zhong GH, Zhu KX, Liao MJ, Hu JL, Li JX, Xu JB, Fan Y, Huang Y, Su YY, Huang SJ, Wang W, Han JL, Jia JZ, Zhu H, Cheng T, Ye XZ*, Li CG*, Wu T*, Zhu FC*, Zhang J*, Xia NS. Immunogenicity and safety of a skin- and neuro-attenuated live vaccine for varicella: a randomized, double-blind, controlled, phase 2a trial. Lancet Infect Dis. 2024. https://doi.org/10.1016/S1473-3099(24)00159-2. (共通讯作者) [3] Zhu F#, Huang S#, Liu X#, Chen Q#, Zhuang C#, Zhao H, # Han J#, Jaen AM, Do TH, Peter JG, Dorado AG, Tirador LS, Zabat GMA, Villalobos REM, Gueco GP, Botha LLG, Iglesias Pertuz SP, Tan J, Zhu K, Quan J, Lin H, Huang Y, Jia J, Chu X, Chen J, Chen Y, Zhang T*, Su Y*, Li C*, Ye X*, Wu T*, Zhang J*, Xia N*; COVID-19-PRO-003 Study Team. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2023 Dec;11(12):1075-1088. (共通讯作者) [4] Zhu FC#, Zhong GH#, Huang WJ#, Chu K, Zhang L, Bi ZF, Zhu KX, Chen Q, Zheng TQ, Zhang ML, Liu S, Xu JB, Pan HX, Sun G, Zheng FZ, Zhang QF, Yi XM, Zhuang SJ, Huang SJ, Pan HR*, Su YY*, Wu T*, Zhang J*, Xia NS*. Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent HPV vaccine and Gardasil 9 in females aged 18-26 years: a randomised blinded clinical trial Brief title: A randomised, blinded clinical trial to compare the immunogenicity of an Escherichia coli-produced 9-valent HPV vaccine with Gardasil 9. Lancet Infect Dis, 2023 Jul 17:S1473-3099(23)00275-X (共通讯作者) [5] Zhao FH#, Wu T#, Hu YM#, Wei LH#, Li MQ#, Huang WJ#, Chen W#, Huang SJ#, Pan QJ, Zhang X, Hong Y, Zhao C, Li Q, Chu K, Jiang YF, Li MZ, Tang J, Li CH, Guo DP, Ke LD, Wu X, Yao XM, Nie JH, Lin BZ, Zhao YQ, Guo M, Zhao J, Zheng FZ, Xu XQ, Su YY, Zhang QF, Sun G, Zhu FC, Li SW, Li YM, Pan HR, Zhang J*, Qiao YL*, Xia NS*. Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Human Papillomavirus (types 16 and 18) L1 Virus-like-particle Vaccine: end-of-study analysis of a phase 3 double-blind, randomized controlled trial. Lancet Infect Dis, 2022 Dec;22(12):1756-1768. (共第一作者) [6] Zhu F#, Zhuang C#, Chu K#, Zhang L#, Zhao H#, Huang S, Su Y, Lin H, Yang C, Jiang H, Zang X, Liu D, Pan H, Hu Y, Liu X, Chen Q, Song Q, Quan J, Huang Z, Zhong G, Chen J, Han J, Sun H, Cui L, Li J, Chen Y*, Zhang T*, Ye X*, Li C*, Wu T*, Zhang J*, Xia N *. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Respir Med, 2022, 10(8): 749-760. (共通讯作者) [7] Hu YM#, Bi ZF#, Zheng Y#, Zhang L#, Zheng FZ#, Chu K, Li YF, Chen Q, Quan JL, Hu XW, Huang XC, Zhu KX, Wang-Jiang YH, Jiang HM, Zang X, Liu DL, Yang CL, Pan HX, Zhang QF, Su YY, Huang SJ, Sun G*, Huang WJ*, Huang Y*, Wu T*, Zhang J, Xia NS. Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial. Sci Bull (Beijing). 2023 Oct 30;68(20):2448-2455. (共通讯作者) [8] Zhang L#, Jiang Y#, He JH#, Chen JY#, Qi RY#, Yuan LZ#, Shao TG#, Zhao H#, Chen CJ, Chen YD, Wang XJ, Lei X, Gao QX, Zhuang CL, Zhou M, Ma J, Liu W, Yang M, Fu R, Wu YT, Chen F, Xiong HL, Nie MF, Chen YY, Wu K, Fang MJ, Wang YB, Zheng ZZ, Huang SJ, Ge SX, Cheng SC, Zhu HC, Cheng T, Yuan Q, Wu T*, Zhang J*, Chen YX*, Zhang TY*, Li CG*, Qi H*, Guan Y*, Xia N*. Intranasal influenza-vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response in hamsters. Nat Commun. 2023 Jul 11;14(1):4117. (共通讯作者) [9] Huang Y#, Tang J, Wang H, Yu H, Song Q, Guo X, Li C, Wang J, Liang C, Li S, Li S, Lin Z, Chen Q, Zhong G, Zhuang S, Su Y, Li T, Wu T*, Ge S*, Zhang J*, Xia N. Pre-existing maternal IgG antibodies as a protective factor against congenital cytomegalovirus infection: A mother-child prospective cohort study. EBioMedicine, 2022.77: 103885. (共通讯作者) [10] Yao XM#, Chen W#, Zhao C#, Wei LH, Hu YM, Li MQ, Lin ZJ, Lin BZ, Liu XH, Hong Y, Li Q, Pan QJ, Zhang X, Li MZ, Zhao YQ, Zhang L, Xu HF, Hu FF, Zhao J, Huang Y, Sheng W, Zheng Y, Hu SY, Su YY, Huang SJ, Pan HR, Zhao FH*, Qiao YL*, Wu T*, Zhang J*, Xia NS*. Naturally acquired HPV antibodies against subsequent homotypic infection: A large-scale prospective cohort study. Lancet Reg Health West Pac, 2021. https://doi.org/10.1016/j.lanwpc.2021.100196(共通讯作者)